Rhythm Pharmaceuticals (RYTM) Stock Price, Quote, News & History

Q: What sector and industry does Rhythm Pharmaceuticals (RYTM) operate in?

Rhythm Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Comments

Rhythm Pharmaceuticals (RYTM) Stock Price, Quote, News & History

RYTMNASDAQ

Logo brought to you by Benzinga Data

Trade with Public

$102.52

-1.18-1.14%

At close: Jan 30, 4:00 PM EST

$102.52

N/A

After Hours: Jan 30, 4:00 PM EST

Overview

News Earnings Options Guidance Analyst Ratings Insider Trades Short Interest Stock Report

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Key Statistics

Open

$102.81

Close

$102.52

Volume / Avg.

667.39K / 765.34K

Day Range

$100.59 - $104.46

52 Wk Range

45.91 - 122.20

Market Cap

$6.84B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

46

Short Interest

11.9%

Days to Cover

8.04

Recent Rhythm Pharmaceuticals Inc News

Rhythm Pharma Strikes Chord As Early PWS Trial Results Show Promise

Rhythm Pharma rises after early Prader-Willi trial data show reduced hunger and BMI, supporting plans for a Phase 3 study of setmelanotide.

Vandana Singh

Diamond Hill Investment Group, Rhythm Pharmaceuticals, Vail Resorts And Other Big Stocks Moving Higher On Thursday

Avi Kapoor

New Obesity Drugs May See Premium Pricing Undermined By Underwhelming Data

Eli Lilly and Novo Nordisk are expected to price their new obesity pills in line with existing injections, as analysts cite affordability, supply capacity, and growing demand in the U.S. market.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-109.13M

Investing Cash Flow (TTM)

-146.34M

Financing Cash Flow (TTM)

259.24M

Free Cash Flow (TTM)

-109.13M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

3.77M

Analyst Trends and Forecast

2

Oct 25

4

Nov 25

5

Dec 25

3

Jan

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$6.58B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

37.79

PB Ratio (TTM)

46.41

Earnings Yield % (TTM)

-3.00%

Earnings Yield % (FWD)

-2.53%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$2.23

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$52.08M

Debt to Equity

0.03

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$102.81

Close

$102.52

Volume / Avg.

667.39K / 765.34K

Day Range

$100.59 - $104.46

52 Wk Range

45.91 - 122.20

Market Cap

$6.84B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

46

Short Interest

11.9%

Days to Cover

8.04

About

Sector

Health Care

Industry

Biotechnology

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, in...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Rhythm Pharmaceuticals (RYTM) stock?

A

You can purchase shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Rhythm Pharmaceuticals (RYTM) competitors?

A

Other companies in Rhythm Pharmaceuticals’s space includes: Immunovant Inc (NASDAQ:IMVT), Avidity Biosciences Inc (NASDAQ:RNA), Celcuity Inc (NASDAQ:CELC), Cogent Biosciences Inc (NASDAQ:COGT) and Alkermes PLC (NASDAQ:ALKS).

Q

What is the forecast, or price target, for Rhythm Pharmaceuticals (RYTM) stock?

A

Rhythm Pharmaceuticals has a consensus price target of $120.69.

Q

What is the current price for Rhythm Pharmaceuticals (RYTM)?

A

The stock price for Rhythm Pharmaceuticals (NASDAQ: RYTM) is $102.52 last updated January 30, 2026 at 4:00 PM EST.

Q

Does Rhythm Pharmaceuticals (RYTM) pay a dividend?

A

There are no upcoming dividends for Rhythm Pharmaceuticals.

Q

When is Rhythm Pharmaceuticals (NASDAQ:RYTM) reporting earnings?

A

Rhythm Pharmaceuticals does not have any upcoming earnings scheduled.

Q

Is Rhythm Pharmaceuticals (RYTM) going to split?

A

There is no upcoming split for Rhythm Pharmaceuticals.

Q

What sector and industry does Rhythm Pharmaceuticals (RYTM) operate in?

A

Rhythm Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

Avidity Biosciences Inc

Cogent Biosciences Inc

Protagonist Therapeutics Inc

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Key Statistics

Open

$102.81

Close

$102.52

Volume / Avg.

667.39K / 765.34K

Day Range

$100.59 - $104.46

52 Wk Range

45.91 - 122.20

Market Cap

$6.84B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

46

Short Interest

11.9%

Days to Cover

8.04

Recent Rhythm Pharmaceuticals Inc News

Rhythm Pharma Strikes Chord As Early PWS Trial Results Show Promise

Rhythm Pharma rises after early Prader-Willi trial data show reduced hunger and BMI, supporting plans for a Phase 3 study of setmelanotide.

Vandana Singh

Diamond Hill Investment Group, Rhythm Pharmaceuticals, Vail Resorts And Other Big Stocks Moving Higher On Thursday

Avi Kapoor

New Obesity Drugs May See Premium Pricing Undermined By Underwhelming Data

Eli Lilly and Novo Nordisk are expected to price their new obesity pills in line with existing injections, as analysts cite affordability, supply capacity, and growing demand in the U.S. market.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-109.13M

Investing Cash Flow (TTM)

-146.34M

Financing Cash Flow (TTM)

259.24M

Free Cash Flow (TTM)

-109.13M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

3.77M

Analyst Trends and Forecast

2

Oct 25

4

Nov 25

5

Dec 25

3

Jan

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$6.58B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

37.79

PB Ratio (TTM)

46.41

Earnings Yield % (TTM)

-3.00%

Earnings Yield % (FWD)

-2.53%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$2.23

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$52.08M

Debt to Equity

0.03

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$102.81

Close

$102.52

Volume / Avg.

667.39K / 765.34K

Day Range

$100.59 - $104.46

52 Wk Range

45.91 - 122.20

Market Cap

$6.84B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

46

Short Interest

11.9%

Days to Cover

8.04

About

Sector

Health Care

Industry

Biotechnology

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, in...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry